The funding for the coronavirus vaccine candidate being developed by Novavax comes as part of Operation Warp Speed.
The federal government is putting $1.6 billion behind drug manufacturer Novavax for development of a coronavirus vaccine, with the goal of delivering 100 million doses by early next year.
The $1.6 billion investment in Novavax, a Maryland-based biotechnology company, for its coronavirus vaccine candidate is part of Operation Warp Speed, an initiative launched by the Trump administration that is designed to speed up development and distribution of a vaccine. The federal government is aiming to begin delivering 300 million doses of a vaccine to the American people by early 2021.
« Adding Novavax’ candidate to Operation Warp Speed’s diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of the year, » Health and Human Services Secretary Alex Azar said in a statement.
